Vivos therapeutics. Jul 1, 2025 · Vivos Therapeutics, Inc.
Vivos therapeutics (VVOS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and Jun 26, 2025 · LITTLETON, Colo. , Aug. If you have been diagnosed with sleep apnea, you need to see a qualified medical doctor and/or a dentist with the appropriate training. Dec 19, 2023 · Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced its official registration with Health Canada, a 3 days ago · Vivos Therapeutics, Inc. Sep 19, 2024 · On Sept. The conference call scheduled to discuss these results will cover strategic collaborations aimed at near-term revenue growth, highlighting the company's proactive approach to enhance its market 2 days ago · Vivos Therapeutics, Inc. (2023, November 29). beats earnings expectations. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. The newly approved devices, which include the flagship DNA (Daytime-Nighttime Appliance) oral appliance, the mRNA oral appliance, and the mmRNA oral Aug 1, 2025 · Vivos Therapeutics, founded in 2016 and based in Littleton, CO, is changing this. Apr 1, 2025 · Discover key insights from Vivos Therapeutics' Q4 2024 earnings: strategic pivots, revenue growth, and expansion plans position them for a profitable 2025. 53 . Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update Mild, moderate, and severe obstructive sleep apnea (OSA) is a serious medical condition that affects patients of all ages, body types, and backgrounds. , Nov. View (VVOS) real-time stock price, chart, news, analysis, analyst reviews and more. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing Jul 30, 2025 · Two Key Hires Add Significant Experience and Strengthen Vivos’ Ability to Scale Its Promising New Sleep Testing Center and Direct Patient Treatment OperationsLITTLETON, Colo. Find the latest Vivos Therapeutics, Inc. Food and Drug Administration Apr 16, 2025 · Vivos Therapeutics, founded in 2016 and based in Littleton, CO, is changing this. , July 01, 2025 Dec 15, 2022 · HIGHLANDS RANCH Colorado, March 03, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. 4 days ago · Vivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. (VVOS) stock, including real-time price, chart, key statistics, news, and more. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company Nov 29, 2023 · With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos Vivos DNA Jun 11, 2025 · Transaction brings OSA diagnostic revenue to Vivos, plus Vivos’ highly effective OSA treatment options to thousands of potential patients in the greater Las Nov 14, 2025 · A high-level overview of Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw its stock soar by 90% following a major regulatory win: the company’s VidaSleep oral appliance has secured approval from the Centers for Medicare Vivos Therapeutics, Inc. Jul 1, 2025 · Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance TreatmentLITTLETON, Colo. Vivos Therapeutics receives first ever FDA 510 (k) clearance for oral device treatment of severe obstructive sleep apnea. Vivos Therapeutics Inc. The appliances are the first to receive FDA clearance for this indication, along with CPAP and myofunctional therapy. If you have NOT yet been diagnosed with OSA, complete our self-assessment survey to be connected with a Nov 29, 2023 · LITTLETON, Colo. , Feb. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to 3 days ago · A detailed overview of Vivos Therapeutics, Inc. Stay ahead with Nasdaq. Wainwright initiated coverage of Vivos Therapeutics (VVOS) with a Buy rating and $7 price target Vivos is a commercial-stage medical device company focused on the commercialization of non Jul 1, 2025 · Vivos Therapeutics, Inc. Aug 20, 2025 · Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo. (VVOS) stock quote, history, news and other vital information to help you with your stock trading and investing. Vivos Therapeutics has your back, and we’re ready to provide the support you need to unlock a better patient service, greater revenue, and more potential for growth. 49, expectations were $-0. Dec 15, 2022 · Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in 3 days ago · Potential Positives Vivos Therapeutics plans to release its third quarter 2025 financial results, which may provide insight into the company's current financial performance and growth trajectory. Visit Vivos provider portals by logging into your account. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company Apr 9, 2024 · LITTLETON, Colo. 19, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. Click here and be first to know! Aug 19, 2025 · About Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in 3 days ago · Call scheduled for today, Wednesday, November 19, 2025, at 5:00 pm ET LITTLETON, Colo. (VVOS) stock news and headlines to help you in your trading and investing decisions. 04, 2023 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive Dec 15, 2022 · Vivos Therapeutics, Inc. Through innovative technology, education, and partnerships with dentists, functional medicine doctors, and sleep specialists, Vivos is empowering healthcare providers to more thoroughly address the complex needs of patients. Aug 19, 2025 · Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ET LITTLETON, Colo. , June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. Food and Drug Administration (FDA) has Apr 16, 2025 · Vivos Therapeutics (NASDAQ: VVOS) said it will acquire the operating assets of The Sleep Center of Nevada (SCN) The firm will pay up to $9 million for the SCN operating assets, including $6 Dec 15, 2022 · Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares HIGHLANDS RANCH Colorado, January 29, 2021 Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods that promote sleep wellness and health Nov 30, 2023 · Vivos Therapeutics offers a line of removable CARE oral appliances that reposition and expand the airway for patients with severe obstructive sleep apnea. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced the U. Get the latest Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and children. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA Careers at Vivos Vivos Therapeutics is dedicated to helping people live, breathe, sleep, and feel better with our multidisciplinary treatment therapy to diagnose and treat dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in Feb 24, 2025 · Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 over CPAP Vivos seeking additional alliances or acquisitions of sleep medicine practices to fuel national expansion objectives LITTLETON, Colo. View real-time stock prices and stock quotes for a full financial overview. is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. Vivos Therapeutics is a medical research and development company focused on breathing wellness. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders Get to know the leadership behind Vivos. Jan 8, 2024 · About Vivos Therapeutics, Inc. Want to experience Vivos quality service? Fill out and submit a contact form to get in touch with us. Vivos Therapeutics, Inc. By addressing the structural causes of OSA, Vivos CARE appliances may prevent the recurrence of symptoms, ensuring you enjoy restful nights for years to come. Here are the filed sec filings for Vivos Therapeutics from Sep 28, 2017 to Aug 18, 2021. C. , July 30, 2025 Aug 14, 2024 · LITTLETON, Colo. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, today announced that it has been granted 510 (k) clearance from the U. stock news by MarketWatch. Food and Sep 19, 2024 · Vivos Therapeutics, Inc. Common Stock (VVOS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all Oct 11, 2023 · Vivos Therapeutics Inc, a medical technology company developing treatments for patients with obstructive sleep apnea (OSA) and snoring, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine. (NASDAQ:VVOS) Q3 2025 Earnings Call Transcript November 19, 2025 Vivos Therapeutics, Inc. Vivos offers a multidisciplinary approach to treat OSA and snoring with oral appliances that reshape and expand the oral cavity. (NASDAQ: VVOS) today announced the closing of its initial public offering of 4,025,000 shares of its common stock. 5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance Apr 8, 2024 · About Vivos Therapeutics, Inc. Reported EPS is $-0. 24, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics Oct 11, 2023 · About Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. , August 14, 2024 – Vivos Therapeutics, Inc. Sep 18, 2024 · Vivos Therapeutics, Inc. Dec 15, 2022 · Colorado, August 23, 2021 Vivos Therapeutics, Inc. Jun 26, 2025 · About Vivos Therapeutics Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring, today announced a View here and know where the nearest provider you can go and contact to! View many providers of Vivos now! Click here! Learn the live VVOS stock price and get the latest news from Vivos Therapeutics available. 29, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. Learn about the Vivos system, how it works, and where to find providers near you. Through innovative technology, education, and collaborations with or acquisitions of functional medicine doctors and sleep specialists, Vivos is empowering healthcare providers to more thoroughly address the complex needs of patients suffering with OSA. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate Dec 15, 2022 · Part of the Vivos System treatment, the mmRNA appliance represents a highly effective, nonsurgical, noninvasive, and nonpharmaceutical. 18, 2024, Vivos Therapeutics announced it received FDA 510(k) clearance for its oral appliance to treat OSA and snoring in children. (VVOS) stock. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in Jun 12, 2024 · Vivos Therapeutics Closes $7. Learn how Vivos devices can improve your breathing, sleep and health with real stories and clinical studies. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the Mar 31, 2025 · About Vivos Therapeutics, Inc. S. Vivos Therapeutics has just reached a monumental milestone: we’ve received FDA 510 (k) clearance for our DNA appliances to treat moderate to severe pediatric obstructive sleep apnea (OSA) and snoring in children aged 6-17. Discover Vivos Therapeutics, an innovative treatment for sleep apnea. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in See the company profile for Vivos Therapeutics, Inc. H. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a Jan 4, 2023 · LITTLETON Colorado, Jan. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced a brand new clearance from the U. Click here to learn more about Vivos Portals now! Oct 31, 2025 · Discover real-time Vivos Therapeutics, Inc. Oct 8, 2024 · About Vivos Therapeutics, Inc. 2 days ago · LITTLETON, Colo. , April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. Here are our best and quality team for Vivos! Read and visit this page now! Dec 5, 2023 · Recently, the FDA granted 510 (k) clearance to Vivos Therapeutics for its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances as a treatment option for patients with severe cases of obstructive sleep apnea (OSA). (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing Oct 24, 2025 · VVOS | Complete Vivos Therapeutics Inc. Patient Benefits: Vivos patient’s report long term success for better sleep and health.